Navigation Links
PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
Date:4/27/2009

evenue to be in the range of $1.080 to $1.100 billion, and earnings per diluted share to be in the range of $0.95 to $1.01. (Previously issued Calendar Year guidance was for service revenue of $1.135 to $1.175 billion, and earnings per diluted share of $0.96 to $1.04).

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures. The Company believes that presenting the non-GAAP financial measures contained in this press release assists investors and others in gaining a better understanding of its core operating results and future prospects, especially when comparing such results to previous periods or forecasted guidance, because such measures exclude items that are outside of the Company's normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. Management uses non-GAAP financial measures, in addition to the measures prepared in accordance with GAAP, as the basis for measuring the Company's core operating performance and comparing such performance to that of prior periods and to the performance of its competitors for the same reasons stated above. Such measures are also used by management in its financial and operating decision-making. Non-GAAP financial measures are not meant to be considered superior to or a substitute for the Company's results of operations prepared in accordance with GAAP.

A conference call to discuss PAREXEL's third quarter earnings, business, and financial outlook will begin at 10:00 a.m. EDT on Tuesday, April 28, 2009 and will be broadcast live over the internet via webcast. The webcast may be accessed in the "Webcasts" portion of the Investors section of the Company's website at www.PAREXEL.com. Users should follow the instructions provided to assure that the necessary audio applications are d
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. PAREXEL Receives BioSingapore Award for Best Performing CRO
2. PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
3. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
4. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
5. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
6. PAREXEL International to Present at the 27th Annual JP Morgan Healthcare Conference
7. PAREXEL Receives Best CRO Award from Scrip
8. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
9. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
10. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
11. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- Tute ... interpretation, today announced an agreement with Lineagen, ... for Lineagen,s NextStep Dx PLUS.  Lineagen, ... and neurological disorders, currently offers FirstStep Dx ... testing service used by healthcare providers as ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... production, announced today the appointment of Michael Bayer, MD, as Director, ... and clinical trial protocols for use by research centers conducting pre-clinical ... ... Diego, CA (PRWEB) January 30, 2009 -- Stemedica Cell Technologies ...
... of future electronic devices could shrink dramatically to one ... many tens of nanometers that characterize today,s most advanced elements ... walls, the ultrathin transition zones that separate regions of a ... , In a material called bismuth ferrite, an unusual compound ...
... this inaugural edition of the BBVA Foundation Frontiers of ... (Austria, 1952) and Ignacio Cirac (Manresa, 1965), "for their ... of the jury chaired by Theodor W. Hnsch, Nobel ... up vital new avenues for the development of quantum ...
Cached Biology Technology:Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services 2Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services 3Domain walls that conduct electricity 2Domain walls that conduct electricity 3Domain walls that conduct electricity 4Domain walls that conduct electricity 5Peter Zoller and Ignacio Cirac, awarded by the BBVA Foundation 2
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP ... Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and ... in United States District Court, Middle District of ... on behalf of a class consisting of all ... Provectus securities between December 17, 2013 and May ...
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... the blinding effects of diabetic retinopathy is pointing toward ... said. Interleukin-6, known to contribute to the ... inflammation of the retina, a first step in a ... working-age adults, MCG researchers reported online in Investigative ...
... Since the time of the earliest humans, people have ... our surroundings and searched for explanations for natural phenomena. ... questions remain to be answered. Although we understand core ... understanding of issues such as how plants maximize their photosynthetic ...
... SCOTTSDALE, Ariz. Jan. 13, 2010 Researchers ... have identified a way to predict which patients with ... The study, Tumor MicroRNA Biomarkers Associated with De ... presented today in San Diego at a joint conference ...
Cached Biology News:Discovery points toward anti-inflammation treatment for blinding disease 2Seeing the forest through the trees and seeing the trees through the leaves 2TGen-Scottsdale Healthcare researchers make breakthrough in lung cancer 2
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Biology Products: